quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:12:31·28d
PRRelease
Zenas BioPharma Inc. logo

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

ZBIO· Zenas BioPharma Inc.
Health Care
Original source

Companies

  • ZBIO
    Zenas BioPharma Inc.
    Health Care

Recent analyst ratings

  • Jan 5UpdateMorgan Stanley$19.00
  • Mar 20UpdateWedbush$35.00
  • Feb 4UpdateWolfe Research$19.00
  • Dec 16UpdateH.C. Wainwright$30.00
  • Nov 5UpdateRodman & Renshaw$34.00
  • Oct 8UpdateGuggenheim$45.00

Related

  • PR6d
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC21d
    Amendment: SEC Form SCHEDULE 13D/A filed by Zenas BioPharma Inc.
  • INSIDER21d
    SEC Form 4 filed by Lu Hongbo
  • INSIDER22d
    SEC Form 4 filed by Fairmount Funds Management Llc
  • INSIDER23d
    SEC Form 4 filed by Moulder Leon O Jr
  • INSIDER23d
    SEC Form 4 filed by Lu Hongbo
  • SEC23d
    Zenas BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
  • SEC25d
    SEC Form 424B5 filed by Zenas BioPharma Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022